Add group to favorites
Back to post list
Send new message to group Search:
Post Subject:
Simvastatin reduces insulin sensitivity in patients with high cholesterol
Simvastatin reduces insulin sensitivity in patients with high cholesterol
x-no-archive: yes
Simvastatin Reduces Insulin Sensitivity in Patients With High Cholesterol
Although simvastatin improves flow-mediated dilation in
hypercholesterolemic patients, the drug reduces adiponectin levels and
insulin sensitivity, according to a report in the April issue of
Diabetes Care. These effects were not dose-dependent and also did not
relate to the magnitude of apolipoprotein B reduction.
In earlier studies, Dr. Kwang Kon Koh and colleagues had shown that
certain drugs, such as fenofibrate and candesartan, increase levels of
adiponectin, a cytokine secreted by fat cells, and enhance insulin
sensitivity. Conversely, in another study, the team found evidence that
simvastatin has exactly the opposite effect.
To explore this further, the researchers assessed adiponectin levels and
insulin sensitivity in 156 hypercholesterolemic patients who were
randomized to receive placebo or simvastatin at one of four doses (10,
20, 40 or 80 mg) during a 2-month period. In addition, flow-mediated
dilation was assessed in all subjects using standard measures.
As anticipated, simvastatin use reduced total cholesterol, LDL
cholesterol, and apolipoprotein B levels, Dr. Koh, from Gachon
University in Incheon, Korea, and colleagues note. In addition, the drug
improved flow-mediated dilation.
By contrast, relative to baseline or placebo, simvastatin reduced
adiponectin levels and insulin sensitivity, independent of the dose or
the drop in apolipoprotein B level.
"Because of reciprocal relationships between endothelial dysfunction and
insulin resistance, we hypothesized that improvements in endothelial
dysfunction may be accompanied by simultaneous improvement in metabolic
parameters," the authors note. This, however, was not the case.
The findings "suggest that not all mechanisms for improving endothelial
dysfunction are tightly coupled to metabolic homeostasis," they add.
Diabetes Care 2008;31:776-782.
x-no-archive: yes
Simvastatin Reduces Insulin Sensitivity in Patients With High Cholesterol
Although simvastatin improves flow-mediated dilation in
hypercholesterolemic patients, the drug reduces adiponectin levels and
insulin sensitivity, according to a report in the April issue of
Diabetes Care. These effects were not dose-dependent and also did not
relate to the magnitude of apolipoprotein B reduction.
In earlier studies, Dr. Kwang Kon Koh and colleagues had shown that
certain drugs, such as fenofibrate and candesartan, increase levels of
adiponectin, a cytokine secreted by fat cells, and enhance insulin
sensitivity. Conversely, in another study, the team found evidence that
simvastatin has exactly the opposite effect.
To explore this further, the researchers assessed adiponectin levels and
insulin sensitivity in 156 hypercholesterolemic patients who were
randomized to receive placebo or simvastatin at one of four doses (10,
20, 40 or 80 mg) during a 2-month period. In addition, flow-mediated
dilation was assessed in all subjects using standard measures.
As anticipated, simvastatin use reduced total cholesterol, LDL
cholesterol, and apolipoprotein B levels, Dr. Koh, from Gachon
University in Incheon, Korea, and colleagues note. In addition, the drug
improved flow-mediated dilation.
By contrast, relative to baseline or placebo, simvastatin reduced
adiponectin levels and insulin sensitivity, independent of the dose or
the drop in apolipoprotein B level.
"Because of reciprocal relationships between endothelial dysfunction and
insulin resistance, we hypothesized that improvements in endothelial
dysfunction may be accompanied by simultaneous improvement in metabolic
parameters," the authors note. This, however, was not the case.
The findings "suggest that not all mechanisms for improving endothelial
dysfunction are tightly coupled to metabolic homeostasis," they add.
Diabetes Care 2008;31:776-782.
Re: Simvastatin reduces insulin sensitivity in patients with high cholesterol
convicted neighbor Susan wrote:
>
> Simvastatin Reduces Insulin Sensitivity in Patients With High Cholesterol
> Although simvastatin improves flow-mediated dilation in
> hypercholesterolemic patients, the drug reduces adiponectin levels and
> insulin sensitivity, according to a report in the April issue of
> Diabetes Care. These effects were not dose-dependent and also did not
> relate to the magnitude of apolipoprotein B reduction.
>
> In earlier studies, Dr. Kwang Kon Koh and colleagues had shown that
> certain drugs, such as fenofibrate and candesartan, increase levels of
> adiponectin, a cytokine secreted by fat cells, and enhance insulin
> sensitivity. Conversely, in another study, the team found evidence that
> simvastatin has exactly the opposite effect.
>
> To explore this further, the researchers assessed adiponectin levels and
> insulin sensitivity in 156 hypercholesterolemic patients who were
> randomized to receive placebo or simvastatin at one of four doses (10,
> 20, 40 or 80 mg) during a 2-month period. In addition, flow-mediated
> dilation was assessed in all subjects using standard measures.
>
> As anticipated, simvastatin use reduced total cholesterol, LDL
> cholesterol, and apolipoprotein B levels, Dr. Koh, from Gachon
> University in Incheon, Korea, and colleagues note. In addition, the drug
> improved flow-mediated dilation.
> By contrast, relative to baseline or placebo, simvastatin reduced
> adiponectin levels and insulin sensitivity, independent of the dose or
> the drop in apolipoprotein B level.
>
> "Because of reciprocal relationships between endothelial dysfunction and
> insulin resistance, we hypothesized that improvements in endothelial
> dysfunction may be accompanied by simultaneous improvement in metabolic
> parameters," the authors note. This, however, was not the case.
>
> The findings "suggest that not all mechanisms for improving endothelial
> dysfunction are tightly coupled to metabolic homeostasis," they add.
>
> Diabetes Care 2008;31:776-782.
It is possible that there was more overeating (during the 2 months) in
the simvastatin treatment group (improved vascular health -->
increased hunger) countering the improvement in endothelial
dysfunction by a worsening in "metabolic parameters" that is due more
to the increase in amount of black fat (VAT) rather than a direct
effect of the simvastatin:
* HeartMDPhD . com /BlackFat
Be hungry... be healthy... be hungrier... be healthier:
* TheWellnessFoundation . com /BeHealthier
Prayerfully in the infinite power and might of the Holy Spirit,
Andrew <><
--
Andrew B. Chung, MD/PhD
Lawful steward of * EmoryCardiology . com
A latter-day disciple of the KING of kings and LORD of lords.
* HeartMDPhD . com /HolySpirit/DiscipleNow
convicted neighbor Susan wrote:
>
> Simvastatin Reduces Insulin Sensitivity in Patients With High Cholesterol
> Although simvastatin improves flow-mediated dilation in
> hypercholesterolemic patients, the drug reduces adiponectin levels and
> insulin sensitivity, according to a report in the April issue of
> Diabetes Care. These effects were not dose-dependent and also did not
> relate to the magnitude of apolipoprotein B reduction.
>
> In earlier studies, Dr. Kwang Kon Koh and colleagues had shown that
> certain drugs, such as fenofibrate and candesartan, increase levels of
> adiponectin, a cytokine secreted by fat cells, and enhance insulin
> sensitivity. Conversely, in another study, the team found evidence that
> simvastatin has exactly the opposite effect.
>
> To explore this further, the researchers assessed adiponectin levels and
> insulin sensitivity in 156 hypercholesterolemic patients who were
> randomized to receive placebo or simvastatin at one of four doses (10,
> 20, 40 or 80 mg) during a 2-month period. In addition, flow-mediated
> dilation was assessed in all subjects using standard measures.
>
> As anticipated, simvastatin use reduced total cholesterol, LDL
> cholesterol, and apolipoprotein B levels, Dr. Koh, from Gachon
> University in Incheon, Korea, and colleagues note. In addition, the drug
> improved flow-mediated dilation.
> By contrast, relative to baseline or placebo, simvastatin reduced
> adiponectin levels and insulin sensitivity, independent of the dose or
> the drop in apolipoprotein B level.
>
> "Because of reciprocal relationships between endothelial dysfunction and
> insulin resistance, we hypothesized that improvements in endothelial
> dysfunction may be accompanied by simultaneous improvement in metabolic
> parameters," the authors note. This, however, was not the case.
>
> The findings "suggest that not all mechanisms for improving endothelial
> dysfunction are tightly coupled to metabolic homeostasis," they add.
>
> Diabetes Care 2008;31:776-782.
It is possible that there was more overeating (during the 2 months) in
the simvastatin treatment group (improved vascular health -->
increased hunger) countering the improvement in endothelial
dysfunction by a worsening in "metabolic parameters" that is due more
to the increase in amount of black fat (VAT) rather than a direct
effect of the simvastatin:
* HeartMDPhD . com /BlackFat
Be hungry... be healthy... be hungrier... be healthier:
* TheWellnessFoundation . com /BeHealthier
Prayerfully in the infinite power and might of the Holy Spirit,
Andrew <><
--
Andrew B. Chung, MD/PhD
Lawful steward of * EmoryCardiology . com
A latter-day disciple of the KING of kings and LORD of lords.
* HeartMDPhD . com /HolySpirit/DiscipleNow
